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Abstract
Introduction: Acute kidney injury (AKI), which is based on ischemic-reperfusion damage, is a widespread life-threat-
ening condition and remains a serious public health problem with a high mortality rate among patients. Despite sig-
nificant advances in various areas of medicine, the prevention and correction of ischemic-reperfusion kidney damage 
are still far from being at the desired level. Pharmacological preconditioning and the use of endothelioprotectors are 
promising areas in this field, therefore the purpose of this study was to analyze the nephroprotective properties of asia-
loerythropoietin and selective inhibitor of arginase II KUD975 in ischemic kidney damage in the experiment.
Materials and methods: The study was performed on 260 white adult male Wistar rats, each weighing 180-220 g. Isch-
emic-reperfusion damage was simulated by applying a clamp on the renal leg for 40 minutes. To determine a degree of cor-
rection caused by morphofunctional disorders traditional functional, biochemical and morphological criteria were used.
Results and discussion: When administering asialoerythropoietin and selective inhibitor of arginase II KUD975, there 
is observed an improvement in the glomerular filtration and microcirculation in the kidneys, decrease in the concentra-
tion of creatinine and urea, a decrease in fractional excretion of sodium and improvement in the histological pattern at 
different periods. The most pronounced nephroprotective effects are observed in the combined use of the test pharma-
cological agents, which are superior to such used in a monotherapy. The use of glibenclamide and L-NAME against the 
background of the correction of the pathology caused by asialoerythropoietin completely eliminates its positive effects. 
When glibenclamide and L-NAME are used against the background of correction of the pathology caused by the selec-
tive inhibitor of arginase II KUD975, its positive effects are completely eliminated by L-NAME. Glibenclamide does 
not eliminate positive effects.
Conclusions: The results of the experiment prove the presence of pronounced nephroprotective properties of asialo-
erythropoietin and selective inhibitor of arginase II KUD975 in ischemic kidney damage in the experiment. The most 
pronounced effects are observed in the combined use of these pharmacological agents. The leading role in causing the 
positive effects from asialoerythropoietin is played by the activation of K+ATP channels and the activation of eNOS. 
The leading role in causing the positive effects from the selective inhibitor of arginase II KUD975 is played by the 
activation of eNOS.
Copyright Elagin VV et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which permits 
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Introduction
Acute kidney damage is a common life-threatening con-
dition that affects one in five hospital patients (Zeng et 
al. 2014) and remains a serious public health problem 
with a high patient mortality rate (Basile and Yoder 2014, 
Kanagasundaram 2015). Delayed risks of acute renal da-
mage include chronic kidney disease (CKD), end-stage 
CKD requiring replacement therapy and transplantation 
(Coca et al. 2012), cardiovascular events (Odutayo et al. 
2017), and deterioration in quality of life (Villeneuve et 
al. 2016).
The leading pathogenetic link of AKI is ischemic and 
reperfusion injury of the kidneys (Khvan 2013, Yu et al. 
2016). Ischemia-reperfusion is a pathological condition 
characterized by an initial decrease in the blood supply to 
the organ, followed by perfusion and repeated oxygenation 
later. With the development of ischemia, there is a decre-
ase in the production of adenosine triphosphate (ATP) and 
intracellular pH, with further development of cell over-
loading with calcium, the generation of reactive oxygen 
species and apoptosis, which is more pronounced in the 
epithelial cells of the proximal tubules. Their damage, in 
turn, leads to tubular-glomerular feedback, which activates 
the renin-angiotensin-aldosterone system and further ag-
gravates vasoconstriction and a decrease in the glomerular 
filtration rate (Munshi et al. 2011, Chatauret et al. 2014).
An important role in the pathophysiology of AKI is 
played by developing disorders of microcirculation and 
endothelial function. Damage to the endothelium of the 
microvascular bed leads to the expression of new mark-
ers on their surface, which contribute to the recruitment 
and adhesion of leukocytes and platelets, which leads to a 
further decrease in perfusion and oxygen delivery and ad-
ditional damage to the endothelial cells and persistence of 
inflammation (Molitoris 2014, Ferenbach and Bonventre 
2015). Endothelial dysfunction is characterized, in partic-
ular, by impaired ability for vasodilation, which is often 
explained by a reduction in the production of nitric oxide. 
One of the enzymes that affect the functional state of the 
endothelium is arginase, which is present in two isoforms: 
arginase I and arginase II (ArgII). Arginase catalyzes the 
hydrolysis of L-arginine to L-ornithine and urea and, thus, 
competes with NOS for the common substrate, L-argi-
nine. In one study, it was demonstrated that the expression 
and activity of arginase II increased significantly after 
ischemia-reperfusion of the kidneys, along with the pro-
gression of renal tissue damage. Pharmacological block-
ade or genetic deficiency of ArgII provided protection 
for the kidneys in this model: animals had lower levels 
of creatinine and plasma urea. Blocking arginases using 
S-(2-boroethyl)-L-cysteine (BEC) reduced the severity of 
histopathological changes, oxidative stress and apoptosis 
processes, the synthesis of pro-inflammatory cytokines; 
increased the formation of nitric oxide and eNOS phos-
phorylation and contributed to the preservation of the mi-
tochondrial ultrastructure. Thus, inhibition of arginaseы 
in acute kidney injury of ischemic-reperfusion genesis is 
one of the promising directions for the correction of this 
kind of damage.
Another important link of AKI pathogenesis is mi-
tochondrial dysfunction, expressed to a greater extent in 
the epithelial cells of the proximal tubules. An increase 
in the production of reactive oxygen species, depletion of 
antioxidants, a change in pyridine nucleotide ratios, fluc-
tuations in the concentration of calcium ions and an incre-
ase in inorganic phosphate in the matrix of mitochondria 
leads to the opening of the mitochondrial pore. The end 
result of its opening is the release of factors activating 
apoptosis (Wayel and Heaton 2004).
One of the universal mechanisms for the prevention 
of ischemic and reperfusion injuries is pharmacological 
preconditioning (PreC). The glycoprotein hormone eryth-
ropoietin is considered as one of the most studied phar-
macological agents with preconditioning properties. The 
main targets of erythropoietin when causing a renoprotec-
tive effect are mitochondrial K+ATP channels (ATP-depen-
dent K+ channels) and NO biosynthesis. Activation of mi-
tochondrial K+ATP channels not only protects mitochondria 
from damage, but also affects the activity of transcription 
factors: increases the expression of HIF (Bahlmann and 
Fliser  2009), reduces the activity of NF-κB (Liao et al. 
2016), and has anti-apoptotic effects (Moore and Bello-
mo 2011). Renoprotective effects of erythropoietin were 
confirmed in a clinical study: the use of erythropoietin at 
a dose of 300 IU/kg in patients during coronary artery by-
pass surgery reduced the incidence of acute kidney injury 
(Song et al. 2009).
Thus, one of the most promising areas in the search 
for potential mechanisms and means to protect the kid-
neys from ischemic and reperfusion injuries is to protect 
the endothelium by restoring the balance of nitric oxide 
and launching preconditioning mechanisms. This make it 
possible to consider the drugs that inhibit the activity of 
arginase II and erythropoietin derivatives with improved 
pharmacokinetic properties and enhanced antihypoxic ac-
tivity. as the most interesting pharmacological agents for 
studying.
Thereby the objective of this study was to analyze the 
nephroprotective action of asialoerythropoietin and selec-
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tive inhibitor of arginase II KUD975 in the condition of 
experimental ischemia-reperfusion. In addition, this study 
looked at the role of K+ATP channels and eNOS in the ne-
phroprotective effects of the test pharmacological agents.
Materials and research methods
Compliance with ethical and regulatory requirements 
in the performance of the research
The experimental part of the research was performed on the 
basis of the vivarium of Kursk State Medical University.
The work was organized and carried out in accordance 
with the following regulatory acts and guidelines govern-
ing the conduct of experimental research in the Russian 
Federation:
1. Order of the Ministry of Healthcare of the Russian Fe-
deration of April 1, 2016 No. 199n “On Approval of 
the Rules of Good Laboratory Practice”
2. GOST 33044-2014 “Principles of Good Laboratory 
Practice” (National Standard of the Russian Federation)
3. GOST 33217-2014 “Guidelines for the Maintenance 
and Care of Laboratory Animals. Rules for Maintenan-
ce and Care of Laboratory Predatory Mammals”
4. “Guidelines for Conducting Pre-clinical Trials of New 
Drugs” (2012) Ed. Mironova AN. Moscow, Grif and Co.
5. The ethical principles of handling laboratory animals 
were in accordance with “The European Convention for 
the Protection of Bertebral Animals Used for Experi-
mental and Other Scientific Purposes. CETS No. 123 “.
Experimental animals
The study was performed on 260 white adult male rats of 
Wistar breed, each weighing 180–220 g. The experiments 
included the rats that had gone thrugh the quarantine re-
gime (14 days) of the vivarium of Kursk State Medical 
University, without showing any signs of acute and chro-
nic diseases.
Simulation of bilateral renal ischemia with subsequent 
reperfusion
After 12 hours of food deprivation, the laboratory 
animal was anesthetized by intraperitoneal injection of 
chloral hydrate (Sigma-Aldrich) at a dose of 300 mg/kg 
of the animal body weight. Then the animal was moved to 
a room with an ambient temperature of at least 250° C and 
was fixed on a heated veterinary table. Ischemia was re-
produced by applying atraumatic vascular clamps on the 
renal pedicles. The correctness of the clamp application 
was controlled by changing the color of the kidneys. A 
wipe moistened with warm 0.9% sodium chloride solution 
was placed on the wound. Forty minutes later, the clamps 
were successively removed, and the microcirculation was 
recorded within five minutes. Next, 4-5 ml of warm 0.9% 
sodium chloride solution was injected into the abdominal 
cavity, and the wound was sutured layer-by-layer. After 
24 or 72 hours of reperfusion, the laboratory animal was 
anesthetized by intraperitoneal injection of chloral hy-
drate at a dose of 300 mg/kg of the animal body weight, 
relaparotomy was performed, microcirculation readings 
were recorded, and blood was sampled from the right 
ventricle for biochemical studies.
Assessment of the level of microcirculation when si-
mulating the pathology
Microcirculation in the cortical layer of the kidneys was 
measured using the MP100 hardware-software complex 
(Biopac System, Inc., USA) with a LDF100C laser Dop-
pler flowmetry (LDF) module and a TSD143 surface sen-
sor, which was applied on the kidney middle part and did 
not affect the area of the kidneyhilum. The microcircula-
tion level was measured immediately after removing the 
vascular clamps from the kidney for 5 minutes, after 24 or 
72 hours of reperfusion, depending on the experimental 
group. Registration and processing of results were per-
formed using AcqKnowledge software 3.8.1. The values 
of the parameters were expressed in perfusion units (PU).
Biochemical markers of acute kidney injury
The level of serum creatinine and urea was determined by 
a photocolorimetric method using standard reagent kits 
from Diakon JSC (Russia) on a URIT800 Vet biochemical 
analyzer (URIT Medical Electronic Co., Ltd., China).
The concentration of sodium ions in the serum was 
determined by the standard method described in manuals 
attached to the sets for an automatic analyzer K/N “Ion 
meter ETs-59” (Russia).
Biochemical analysis of urine. Calculation of endogen-
ous creatinine clearance (glomerular filtration rate) 
and fractional excretion of sodium.
To obtain urine samples, the animals were placed in me-
tabolic cells with free access to water for 12 or 24 hours. 
Next, diuresis was measured, and samples were taken for 
further study.
Endogenous creatinine clearance (glomerular filtration 
rate (GFR) was calculated as follows (Formula 1):
Formula 1. Formula for calculating the glomerular filtra-
tion rate
Fractional excretion of sodium (FENa) was calculated 
using the following formula (Formula 2):
Formula 2. Formula for calculating the fractional excre-
tion of sodium
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Morphological methods for assessing changes in the 
kidneys
For histological examination, the obtained cadaver mate-
rial was fixed in 10% neutral buffered formalin solution. 
When fixation is done, a tissue sample (1x1 cm) was dis-
sected out of the biomaterial, embedded in paraffin using 
a standard procedure, and the sections of 5–7 μm thick 
were made.
The obtained histological sections were stained with 
hematoxylin and eosin, according to the method of van 
Gieson, according to Mallory.
Microscopic examination and photographing were 
carried out using an optical system consisting of a Lei-
ca CME microscope and a DCM-510 eyepiece camera 
magnifying x100, x200 and x400 times, with the images 
documented in the FUTURE WINJOE software supplied 
with the eyepiece camera.
The morphometric study included the determination of 
the following indicators: on micrographs, using the Ima-
goJ software,  the height of epithelial cells in the proximal 
and distal parts of the nephron was measured, as well as 
the cross-sectional area of the renal corpuscle, vascular 
glomerulus and subcapsular space.
Study design. The choice of administration modes for 
pharmacological agents
The study of the activity of asialoerythropoietin (Protein 
Contour Company Ltd.) was carried out at doses of 0.4 
µg/kg and 2.4 µg/kg once, 30 minutes before simulating 
ischemia. The dose of 0.4 µg/kg is selected based on the 
minimum effective dose of erythropoietin, equivalent to 
50 IU of erythropoietin, and the dose of 2.4 µg/kg cor-
responds to the maximum recommended dose of erythro-
poietin in humans (300 IU/kg).
KUD975 activity (10 mg film-coated tablets) was test-
ed at doses of 1 mg/kg and 3 mg/kg once intragastrically, 
120 minutes before ischemia simulation. The dose of 1 
mg/kg was chosen based on the recalculation of the po-
tential minimum dose recommended for use in humans, 3 
mg/kg is the dose that demonstrated pronounced protec-
tive properties in other experimental models. The mode 
of administration is based on the pharmacokinetic profile 
of the drug.
Recombinant erythropoietin (Epokrin, The State Re-
search Institute of Highly Pure Biopreparations) was ad-
ministered subcutaneously at a dose of 50 IU/kg once, 30 
minutes before ischemia simulation. The dose and mode 
of administration were selected based on the previous-
ly identified protective effects on ischemia-reperfusion 
models (Dolzhikova 2013).
L-norvaline was administered intraperitoneally at a 
dose of 100 mg/kg once, 30 minutes before simulating 
ischemia. The dose and mode of administration are jus-
tified by the protective effects confirmed in the previous 
experimental studies (Pokrovsky et al. 2013, 2014).
The blocker of ATP-dependent K+ channels – gliben-
clamide (Maninil, Berlin-Chemie AG) was administered 
intragastrically at a dose of 50 mg/kg 30 minutes before 
the administration of the pharmacological agents.
The eNOS inhibitor N-nitro-L-arginine methyl ester 
(Sigma Aldrich, USA) was administered at a dose of 25 
mg/kg 30 minutes before the administration of the phar-
macological agents.
The animals were randomized by weight and formed 
into the following experimental groups of 10 each:
1. Sham (sham-operated) (1 day)
2. Sham (sham-operated) (3 days)
3. Control (ischemia-reperfusion) (1 day)
4. Control (ischemia-reperfusion) (3 days)
5. AsEPo (asialoerythropoietin) 0.4 µg/kg (1 day)
6. AsEPo (asialoerythropoietin) 0.4 µg/kg (3 days)
7. AsEPo (asialoerythropoietin) 2.4 µg/kg (1 day)
8. AsEPo (asialoerythropoietin) 2.4 µg/kg (3 days)
9. KUD975 1 mg/kg (1 day)
10. KUD975 1 mg/kg (3 days)
11. KUD975 3 mg/kg (1 day)
12. KUD975 3 mg/kg (3 days)
13. EPo 50 IU (recombinant erythropoietin 50 IU) (1 day)
14. EPo 50 IU (recombinant erythropoietin 50 IU) (3 
days)
15. L-Norvaline 100 mg/kg (1 day)
16. L-Norvaline 100 mg/kg (3 days)
17. AsEPo 2.4 µg/kg + KUD975 3 mg/kg (1 day)
18. AsEPo 2.4 µg/kg + KUD975 3 mg/kg (3 days)
19. AsEPo 2.4 µg/kg + glibenclamide 50 mg/kg (1 day)
20. AsEPo 2.4 µg/kg + glibenclamide 50 mg/kg (3 days)
21. AsEPo 2.4 µg/kg + L-NAME 25 mg/kg (1 day)
22. AsEPo 2.4 µg/kg + L-NAME 25 mg/kg (3 days)
23. KUD975 3 mg/kg (1 day) + L-NAME 25 mg/kg
24. KUD975 3 mg/kg (3 days) + L-NAME 25 mg/kg
25. KUD975 3 mg/kg (1 day) + glibenclamide 50 mg/
kg (1 day)
26. KUD975 3 mg/kg (3 days) + glibenclamide 50 mg/
kg (3 days)
The protocol consisted of the following sections:
1. Simulation of bilateral ischemia of the kidneys with 
subsequent reperfusion within 24 or 72 hours and their 
correction using asialoerythropoietin and selective in-
hibitor of arginase  II KUD975.
2. Measurement of microcirculation within the first five 
minutes of reperfusion.
3. Urine collection for 12 or 24 hours, followed by 
measuring diuresis and biochemical parameters (after 
12 or 48 hours of reperfusion).
4. After 24 or 72 hours in anesthesia with chloral hydra-
te, the assessment of renal microcirculation, sampling 
venous blood for biochemical studies and calculating 
GFR, and also recovering kidney tissues for pathologi-
cal studies.
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Statistical processing of research results
Descriptive statistics methods were applied to all the 
data: the data was checked for normal distribution. The 
type of distribution was determined by the Shapiro-Wilk 
criterion. In the case of a normal distribution, the mean 
value (M) and standard error of the mean (m) were calcu-
lated. Intergroup differences were analyzed by parametric 
(Student’s t-test) or non-parametric (Mann-Whitney test) 
methods, depending on the type of distribution. The sta-
tistical significance of the differences between morpho-
logical changes after their ranking was evaluated using 
the Mann-Whitney method of analyzing non-parametric 
data (Glanz 1999, Sydorenko 2003). All the calculations 
were performed using the statistical package of Microsoft 
Excel 7.0.
Results and discussion
Nephroprotective effects of asialoerythropoietin and 
selective inhibitor of arginase II KUD975 in experi-
mental renal ischemia
In the control animals group (ischemia-reperfusion), 24 
hours after ischemia there was no statistically significant 
increase in serum creatinine level; however, there was a 
drop in the glomerular filtration rate from 0.51±0.03 ml/
min in the group of sham-operated animals to 0.17±0.02 
ml/min. After 72 hours, there was a progressive decrease 
in the filtration capacity of the kidneys, which showed in 
an increase in the level of serum creatinine to 120±3.45 
μmol/l and a 8.2-time decrease in the glomerular filtration 
rate from 0.49±0.03 ml/min in the group of sham-operat-
ed animals to 0.06±0.01 ml/min (p<0.05).
The administration of asialoerythropoietin at doses of 
0.4 µg/kg and 2.4 µg/kg 30 minutes before the induction 
of ischemia led to an increase in the glomerular filtration 
rate to 0.32±0.04 ml/min and 0.37±0.03 ml/min after 24 
hours of reperfusion, respectively, which was statistically 
significantly different from that in the group of control 
animals (p<0.05) (Fig. 1a). The introduction of a selec-
tive inhibitor of arginase II against the background of 
simulating ischemia-reperfusion of the kidneys also led 
to a significant increase in the glomerular filtration rate to 
0.24±0.02 ml/min and 0.31±0.03 ml/min after 24 hours of 
reperfusion at doses of 1 mg/kg and 3 mg/kg, respective-
ly. The test drugs had no effect on the serum creatinine 
level on the first day.
After 72 hours of reperfusion, a dose-dependent im-
provement in the filtration capacity of the kidneys was 
also observed, which was expressed in a statistically sig-
А
C D
B
Figure 1. The effect of the test drugs on the glomerular filtration rate 24 after ischemia (A), 72 hours after ischemia (B), creatinine 
concentration 72 hours after ischemia (C), serum urea concentration 24 hours after ischemia (D). Notes: x – p<0.05 compared with 
the sham (sham-operated) group of animals; y – p<0.05 compared with the control group (ischemia-reperfusion); EPo – erythropoi-
etin; AsEPo – asialoerythropoietin.
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nificant (p<0.05) decrease in the concentration of serum 
creatinine to 73.9±2.7 μmol/l and 63.1±2.2 μmol/l ( Fig. 
1C) and recovery of glomerular filtration rate to 0.27±0.02 
ml/min and 0.36±0.03 ml/min (Fig. 1B) against the back-
ground of using asialoerythropoietin in the test doses, 
respectively. When using KUD975 in the test doses, 
there was a statistically significant decrease (p<0.05) in 
the concentration of serum creatinine to 81.3±2.8 μmol/l 
and 73.7±2.22 μmol/l and recovery of the glomerular fil-
tration rate to 0.22±0.02 ml/min and 0.26±0.02 ml/min, 
respectively. The activity of the test drugs significantly 
exceeded the nephroprotective properties of the compari-
son drugs (Fig. 1).
A study of the serum urea concentration showed that 
the simulation of a 40-minute bilateral model of kidney 
ischemia-reperfusion led to an increase in this indicator 
after 24 hours of reperfusion from 5.35±0.21 mmol/l to 
9.7±0.68 mmol/l (Fig. 1D), which was somewhat leveled 
after 72 hours, reaching a level of 8.33±0.23 mmol/l.
Under the influence of asialoerythropoietin, a statis-
tically significant (p<0.05) decrease in the serum urea 
concentration occurred both on the first and the third day 
of the experiment, reaching at a single dose of 2.4 μg/
kg 5.97±0.25 mmol/l and 6.76±0.33 mmol/l after 24 and 
72 hours of reperfusion, respectively. Under the influ-
ence of KUD975, a statistically significant (p<0.05) de-
crease in the serum urea concentration occurred both on 
the first and third days of the experiment, reaching with 
a single prophylactic administration at a dose of 3 mg/kg 
6.47±0.37 mmol/l and 6.9±0.23 mmol/l after 24 and 72 
hours of reperfusion, respectively.
When assessing the functional state of the renal tu-
bules, the rate of fractional excretion of sodium in the 
group of sham-operated animals increased slightly 
from 0.38±0.02% to 0.5±0.02%, which may be due to 
the mobilization of sodium in the postoperative period. 
Simulation of acute kidney injury of ischemic-reperfu-
sion genesis led to an increase in FeNa to 2.24±0.12% 
to 7.4±0.78% after 24 and 72 hours of reperfusion, re-
spectively (Table 1), which together with a decrease in 
glomerular rate filtering may indicate the development of 
acute tubular necrosis. Against the background of the use 
of asialoerythropoietin, a dose-dependent 2.2- and 2.5-
time decrease in the fractional excretion of sodium was 
observed on the first days of the experiment, exceeding 
the protective effects of erythropoietin. On the 3rd day of 
the experiment, the correction with asialoerythropoietin 
made it possible to achieve the target values of fractional 
excretion of sodium of less than 2% to 1.57±0.09% and 
1.3±0.09% at doses of 0.4 μg/kg and 2.4 μg/kg, respec-
tively. The use of KUD975 at doses of 1 mg/kg and 3 
mg/kg led to an improvement in the functional state of 
the renal tubules recorded by a decrease in the fraction-
al excretion of sodium, which was more pronounced on 
the 3rd day of the experiment and was 2.27±0.17% and 
1.8±0.09%, respectively.
The dynamics of microcirculatory disorders in the 
kidneys corresponded to the dynamics of biochemical 
and functional parameters: in the group of sham-operat-
ed animals it was 904.6±60.43 PU, 870±96.48 PU and 
859±67.98 PU 5 minutes, 24 hours and 72 hours after the 
experiment onset, respectively. Simulation of acute kid-
ney injury resulted in a statistically significant reduction 
in microcirculation to 209±24.42 PU after 5 minutes of 
reperfusion, followed by recovery to 418.1±46.02 PU and 
315.5±13.67 PU after 24 and 72 hours of reperfusion, 
respectively. A single injection of asialoerythropoietin at 
doses of 0.4 mg/kg and 2.4 mg/kg for 30 minutes and se-
lective inhibitor of arginase II KUD975 at doses of 1 mg/
kg and 3 mg/kg for 120 minutes before ischemia result-
ed in the restoration of the microcirculation level at all 
time points of the experiment, statistically exceeding the 
performance of the group which received the comparison 
drugs (p<0.05) (Table 2).
A morphological study revealed a decrease in the 
height of the epithelium of the proximal and distal tubules 
in animals with ischemia-reperfusion of the kidneys both 
on the 1st day and on the 3rd day. When used for the cor-
rection of the test pharmacological agents, a statistically 
significant increase in the height of the epithelium of the 
proximal and distal tubules occurs, but it does not reach 
the target level (Table 3).
Nephroprotective effects of a combination of asialoe-
rythropoietin and a selective inhibitor of arginase II in 
experimental renal ischemia
A combined therapy with asialoerythropoietin at a dose 
of 2.4 kg / kg and KUD975 at a dose of 3 mg/kg helped 
to improve the filtration capacity of the kidneys, which is 
superior by effecacy to the monotherapy with these drugs. 
So, on day 1 of the experiment, the glomerular filtration 
rate increased to 0.45±0.03 ml/min, being not significant-
ly different from the indicators of sham-operated animals 
(Fig. 2A).
On the 3rd day of the experiment, the combination ther-
apy with asialoerythropoietin and KUD975 exceeded the 
efficacy of the monotherapy with these drugs, which was 
expressed in the form of normalization of creatinine to 
61±2.17 µmol/L and an increase in glomerular filtration 
rate to 0.42±0.03 ml/min.
Table 1. Dynamics of fractional excretion of sodium against the 
background of correction with asialoerythropoietin and selec-
tive inhibitor arginase II KUD975 (M±m; n=10)
Experimental group Day 1 Day 3 
Sham 0.38±0.02% 0.5±0.02%
Control 2.24±0.12%x 7.4±0.78%x
EPo 50 МЕ 1.42±0.11%xy 2.5±0.09%xy
AsEPo 0.4 µg/kg 1.03±0.11%xy 1.57±0.09%xy
AsEPo 2.4 µg/kg 0.91±0.09%xy 1.3±0.09%xy
L-Norvaline 100 mg/kg 1.42±0.13%xy 2.76±0.21%xy
KUD975 1 mg/kg 1.16±0.12%xy 2.27±0.17%xy
KUD975 3 mg/kg 1.14±0.11%xy 1.8±0.09%xy
Notes: x – р<0.05 compared with the sham (sham-operated) group of 
animals; y – p<0.05 compared with the control group (ischemia-reperfu-
sion); EPo – erythropoietin; AsEPo – asialoerythropoietin.
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Table 2. Dynamics of microcirculation indicators in the kidneys against the background of the correction with asialoerythropoietin 
and selective inhibitor of arginase II KUD975 (M±m; n=10)
Experimental group Microcirculation rate, PU
5 minutes Day 1 Day 3 
Sham 904.5±60.43 870.5±96.18 859±67.98
Control 209±24.42x 418.1±46.02x 315.5±13.67x
EPo 50 МЕ 459.8±24.06xy 662.9±22.71xy 490.5±21.81xy
AsEPo 0.4 µg/kg 489.6±33.65xy 636.4±20.93xy 521.8±20.78xy
AsEPo 2.4 µg/kg 670.4±54.19xy 725.6±47.41y 689.3±46.52y
L-Norvaline 100 mg/kg 437.9±29.1xy 657.9±18.81xy 441.4±11.63xy
KUD975 1 mg/kg 431.1±32.95xy 691.8±2347y 485±16.42xy
KUD975 3 mg/kg 604.7±43.51xy 718.2±44.52y 653.6±61.99xy
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y - p<0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
Table 3. Dynamics of the height of the epithelium of the proximal and distal tubules against the background of the correction with 
asialoerythropoietin and selective inhibitor of arginase II KUD975 (M±m; n=10)
Group
24 hours 72 hours
Epithelium height of 
the proximal tubules
Epithelium height of the 
distal tubules
Epithelium height of 
the proximal tubules
Epithelium height of 
the distal tubules
Sham 11.28±1.56 7.08±1.43 11.28±1.56 7.08±1.43 
Control 8.21±0.21x 6.46±0.15x 6.56±0.74x 4.24±0.73x
EPo 50 МЕ 8.7±0.1xy 6.58±0.09x 8.25±0.1 5.65±0.09xy
AsEPo 0.4 µg/kg 9.52±0.12xy 6.63±0.09x 9.39±0.08xy 6.28±0.09xy
AsEPo 2.4 µg/kg 9.72±0.11xy 6.65±0.09x 9.93±0.07xy 6.33±0.09xy
L-Norvaline 100 mg/kg 8.38±0.1x 6.5±0.08x 7.98±0.1xy 5.55±0.1xy
KUD975 1 mg/kg 9.33±0.1xy 6.54±0.09 x 8.29±0.09xy 5.96±0.09xy
KUD975 3 mg/kg 9.4±0.09xy 6.61±0.09x 8.57±0.1xy 6.19±0.1xy
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y - p<0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
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Figure 2. The effect of the test drugs on the glomerular filtration rate after 24 after ischemia (A), after 72 hours (B), creatinine con-
centration after 72 hours (C), serum urea concentration after 24 hours (D). Notes: x – р<0.05 in comparison with the sham (sham 
operated) animals; y – p<0.05 compared with the control group (ischemia-reperfusion); EPo – erythropoietin; AsEPo – asialoeryth-
ropoietin.
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The serum urea concentration against the background 
of combined pharmacotherapy using asialoerythropoie-
tin and selective inhibitor of arginase II KUD975 de-
creased and reached 5.67±0.19 mmol/L and 6.13±0.16 
mmol/L after 24 and 72 hours of reperfusion, respecti-
vely. The efficacy of pharmacotherapy surpassed that of 
monotherapy regimens with these drugs.
Against the background of correction with asia-
loerythropoietin and selective inhibitor of arginase II 
KUD975, tubular dysfunction was leveled, resulting 
in a decrease in the fractional excretion of sodium to 
0.65±0.04% and 0.8±0.04% after 24 and 72 hours of 
reperfusion, respectively. These indicators were signi-
ficantly different from those of animals in the groups 
with correction with asialoerythropoietin or KUD975 
(Table 4).
A single prophylactic use of a combination of asia-
loerythropoietin and selective inhibitor of arginase II 
KUD975 resulted in the restoration of the level of micro-
circulation at all time points of the experiment, exceeding 
the indicators of the group using these drugs in a mono-
therapy (Table 5).
The morphological study revealed that an increase in 
the height of the epithelium of the proximal and distal 
tubules in animals with a combined use of asialoeryth-
ropoietin and selective inhibitor of arginase II KUD975 
is even more pronounced than in animals treated with a 
monotherapy (Table 6).
The role of eNOS and K+ATP channels in inducing the 
nephroprotective effects of asialoerythropoietin and 
selective inhibitor of arginase II in experimental ische-
mia-reperfusion of the kidneys
The administration of the K+ATP blocker of glibenclamide 
channels completely eliminated the positive effects of asia-
loerythropoietin, which was expressed in a decrease in the 
glomerular filtration rate and had no nephroprotective ef-
fects of the selective inhibitor of arginase II. The use of an 
endothelial NO synthase inhibitor, L-NAME 30 minutes 
before the administration of the pharmacological agents le-
veled the positive effects of both asialoerythropoietin and 
KUD975 to the level of the indicators of the GFR group 
with simulated ischemia-reperfusion (Fig. 3A). 
Table 5. Dynamics of indicators of microcirculation in the kidneys against the background of the correction with asialoerythropoi-
etin and selective inhibitor of arginase II KUD975 (M±m; n=10)
Experimental group Microcirculation rate, PU
5 minutes Day 1 Day 3 
Sham 904.5±60.43 870.5±96.18 859±67.98
Control 209±24.42x 418.1±46.02x 315.5±13.67x
AsEPo 2.4 µg/kg 670.4±54.19xy 725.6±47.41y 689.3±46.52y
KUD975 3 mg/kg 604.7±43.51xy 718.2±44.52y 653.6±61.99xy
AsEPo 2.4 µg/kg + KUD975 3 mg/kg 803.4±25.23y 775.5±29.13y 801.3±20.16y
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y – p<0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
Table 6. Dynamics of the height of epithelium of the proximal and distal tubules against the background of the correction by the 
combination of asialoerythropoietin and selective inhibitor of arginase II KUD975 (M±m; n=10)
Group 24 hours 72 hours
Epithelium height of 
the proximal tubules
Epithelium height of 
the distal tubules
Epithelium height of 
the proximal tubules
Epithelium height of 
the distal tubules
Sham 11.28±1.56 7.08±1.43 11.28±1.56 7.08±1.43 
Control 8.21±0.21x 6.46±0.15x 6.56±0.74x 4.24±0.73x
AsEPo 2.4 µg/kg 9.72±0.11xy 6.65±0.09x 9.93±0.07xy 6.33±0.09xy
KUD975 3 mg/kg 9.4±0.09xy 6.61±0.09x 8.57±0.1xy 6.19±0.1xy
AsEPo 2.4 µg/kg + KUD975 3 mg/kg 10.32±0.14xy 6.9±0.08y 10.66±0.11y 6.85±0.11y
Notes: x – р<0,05 in comparison with the sham (sham operated) animals; y – p<0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
Table 4. Dynamics of the fractional excretion of sodium against the background of the correction with asialoerythropoietin and 
selective inhibitor of arginase II KUD975 (M±m; n=10)
Experimental group Day 1 Day 3 
Sham 0.38±0.02% 0.5±0.02%
Control 2.24±0.12%x 7.4±0.78%x
AsEPo 2.4 µg/kg 0.91±0.09%xy 1.3±0.09%xy
KUD975 3 mg/kg 1.14±0.11%xy 1.8±0.09%xy
AsEPo 2.4 µg/kg + KUD975 3 mg/kg 0.65±0.04%xy 0.8±0.04%xy
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y – p<0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
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After 72 hours of reperfusion, a similar trend was ob-
served: against the background of using glibenclamide, 
the protective effects of asialoerythropoietin were leve-
led, which manifested itself in the growing creatinine le-
vel and a decrease in glomerular filtration rate to the level 
of the indicators of the control group. In the group with 
the introduction of glibenclamide and KUD975, the in-
dex of glomerular filtration rate did not significantly differ 
from those of the group with pathology simulation and the 
use of KUD975, reaching 0.3±0.02 ml/min. Preliminary 
administration of L-NAME led to the elimination of the 
nephroprotective properties of both asialoerythropoietin 
and selective inhibitor of arginase II (Fig. 3B).
The serum urea concentration also increased against 
the background of prior administration of the eNOS in-
hibitor, both in the groups treated for correction with 
asialoerythropoietin and in the groups using KUD975; 
however, the blockade of K+ATP channels did not lead 
to an increase in the level of urea in the group against the 
background of the KUD975 correction.
When assessing the functional state of the renal tubu-
les, there was an increase in damage to the tubular ap-
paratus in the group with the preliminary administration 
of glibenclamide during the use of asialoerythropoietin, 
and no dynamics against the use of the selective inhibitor 
of arginase II. The blockade of NO synthesis led to the 
leveling of the effects of both classes of drugs, which was 
expressed in an increased fractional excretion of sodium 
both after 24 and 72 hours of reperfusion (Table 7).
At all time intervals, when measuring the level of mi-
crocirculation against the background of the introduction of 
glibenclamide, the disappearance of the protective effects of 
asialoerythropoietin was observed, expressed in the growth 
of microcirculatory disorders to reach the indicators of the 
control group. In the group with a prophylactic administrati-
on of KUD975, K+ATP channels had no contribution to the 
realization of nephroprotective properties. Preliminary admi-
nistration of L-NAME at a dose of 25 mg/kg led to the eli-
mination of the nephroprotective properties of both asialoe-
rythropoietin and selective inhibitor of arginase II (Table 8).
The morphological study revealed that the height 
of the epithelium of the proximal and distal tubules du-
ring the correction with asialoerythropoietin against the 
background of glibenclamide and L-NAME approaches 
the parameters of the animals in the control group. When 
correcting by means of selective inhibitor of arginase II 
KUD975 against the background of glibenclamide, the ef-
fect of the therapy is maintained; whereas when correcting 
by means of selective inhibitor of arginase II KUD975 
against the background of L-NAME it is leveled (Table 9).
Figure 3. Effect of the test drugs against the background of glibenclamide and L-NAME on the glomerular filtration rate 24 after 
ischemia (A), after 72 hours (B), creatinine concentration after 72 hours (C), serum urea concentration after 24 after ischemia (D). 
Notes: x – p<0.05 compared with the sham (sham-operated) group of animals; y – p<0.05 compared with the control group (isch-
emia-reperfusion); EPo – erythropoietin; AsEPo – assayed erythropoietin.
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The results obtained indicate the dose-dependent 
nephroprotective properties of asialoerythropoietin. The 
protective effects of asialoerythropoietin are explained 
by its ability to bind to heterodimeric receptors for ery-
thropoietin (Carelli et al. 2011, Yakovlev et al. 2016) and 
exert an anti-apoptotic, antioxidant effect (Kaneko et al. 
2013, Gaddam et al. 2013), a preconditioning effect (Ka-
pitsinou and Haase 2015, Oba et al. 2015, Heyman et al. 
2016, Khaksari et al. 2017) and an ability to restore the 
system of NO synthesis (Elshiekh et al. 2017).
Selective inhibitor of arginase II KUD975 also showed 
dose-dependent nephroprotective effects. They are asso-
ciated with blockade of arginase II. When this occurs, 
eNOS is activated, which leads to the correction of endo-
thelial dysfunction (Suwanpradid et al. 2014, Rath et al. 
2014, Pandey et al. 2014, Nara et al. 2015, Krause et al. 
2015, Steppan et al. 2016).
The high efficacy of the combined therapy can be ex-
plained by the effect of drugs on various pathogenetic links 
of ischemic and reperfusion kidney injuries with activa-
ting the mechanisms of pharmacological preconditioning 
and implementation of endothelium protective effects.
The leveling of the positive effects of asialoerythro-
poietin against the background of using glibenclamide 
and L-NAME, which could have been anticipated in 
advance, is explained by the fact that its mechanism of 
action has endothelium-protective properties and an abi-
lity to activate K+ATP channels. When using selective 
inhibitor of arginase II KUD975 against the background 
of glibenclamide, the leveling of its nephroprotective ef-
fects does not happen, because they are induced through 
the activation of eNOS, which is confirmed by the leve-
ling of positive effects against the background of using 
L-NAME.
Table 7. Dynamics of fractional excretion of sodium in the experimental groups (М±m; n=10).
Experimental group Day 1 Day 3 
Sham 0.38±0.02% 0.5±0.02%
Control 2.24±0.12%x 7.4±0.78%x
AsEPo 2.4 µg/kg 0.91±0.09%xy 1.3±0.09%xy
AsEPo 2.4 µg/kg + glibenclamide 2.03±0.13%x 6.59±0.45%x
AsEPo 2.4 µg/kg + L-NAME 1.94±0.14%x 5.94±0.34%x
KUD975 3 mg/kg 1.14±0.11%xy 1.8±0.09%xy
KUD975 3 mg/kg + L-NAME 2.13±0.18%x 6.77±0.54%x
KUD975 3 mg/kg + glibenclamide 1.01±0.07%xy 1.84±0.11%xy
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y – p <0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
Table 8. Dynamics of indicators of microcirculation in the kidneys against the background of correction with asialoerythropoietin 
(М±m; n=10)
Experimental group Microcirculation rate, PU
5 minutes Day 1 Day 3 
Sham 904.5±60.43 870.5±96.18 859±67.98
Control 209±24.42x 418.1±46.02x 315.5±13.67x
AsEPo 2.4 µg/kg 670.4±54.19xy 725.6±47.41y 689.3±46.52y
AsEPo 2.4 µg/kg + glibenclamide 215.9±18.9x 421.4±24.62x 329.2±28.05x
AsEPo 2.4 µg/kg + L-NAME 227.2±18.8x 451.8±30.70x 334.7±20.25x
KUD975 3 mg/kg 604.7±43.51xy 718.2±44.52y 653.6±61.99xy
KUD975 3 mg/kg + L-NAME 220.9±22.47x 437.9±31.39x 323±25.43x
KUD975 3 mg/kg + glibenclamide 615.2±28.74xy 717.6±25.73y 652.1±46.33xy
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y – p <0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
Table 9. Dynamics of the epithelium height of the proximal and distal tubules when correcting with asialoerythropoietin and selec-
tive inhibitor of arginase II KUD975 against the background of glibenclamide and L-NAME (М±m; n=10)
Group
24 hours 72 hours
Epithelium height of 
the proximal tubules
Epithelium height of 
the distal tubules
Epithelium height of 
the proximal tubules
Epithelium height of 
the distal tubules
Sham 11.28±1.56 7.08±1.43 11.28±1.56 7.08±1.43 
Control 8.21±0.21x 6.46±0.15x 6.56±0.74x 4.24±0.73x
AsEPo 2.4 µg/kg 9.72±0.11xy 6.65±0.09x 9.93±0.07xy 6.33±0.09xy
AsEPo 2.4 µg/kg + glibenclamide 50 mg/kg 8.66±0.16x 6.57±0.09x 6.79±0.11x 4.37±0.11x
AsEPo 2.4 µg/kg + L-NAME 25 mg/kg 8.79±0.19x 6.62±0.09x 6.85±0.11x 4.57±0.13x
KUD975 3 mg/kg 9.4±0.09xy 6.61±0.09x 8.57±0.1xy 6.19±0.1xy
KUD975 3 mg/kg + L-NAME 25 mg/kg 8.68±0.2x 6.45±0.09x 6.84±0.11x 4.48±0.11x
KUD975 3 mg/kg + glibenclamide 50 mg/kg 9.13±0.15xy 6.6±0.09x 8.27±0.13xy 6.03±0.09xy
Notes: x – р<0.05 in comparison with the sham (sham operated) animals; y – p<0.05 compared with the control group (ischemia-reperfusion); EPo 
– erythropoietin; AsEPo – asialoerythropoietin.
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Conclusions
The obtained results testify to the dose-dependent nephro-
protective properties of asialoerythropoietin and selective 
inhibitor of arginase II KUD975, the efficacy of which 
exceeds the effect of the comparison drugs.
Prevention of ischemic and reperfusion kidney injuries 
with a combination of asialoerythropoietin at a dose of 
2.4 µg/kg and a selective inhibitor of arginase II KUD975 
at a dose of 3 mg/kg is superior by efficacy to the mono-
therapy regimens with these drugs.
The results obtained indicate that the nephroprotective 
properties of asialoerythropoietin are induced through ac-
tivation of the K+ATP channels and the NO system, which 
was demonstrated in the experiments with glibenclamide 
and the eNOS blocker, respectively. The mechanism of 
the nephroprotective effects of the selective inhibitor of 
arginase II is also closely related to the nitric oxide system 
and does not depend on K+ATP channels.
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